Phoenix
Recovery/inflammation blend for convenience; the clinical synergy of the trio is not proven.
Updated:
Affiliate link to this product’s page on Peptira. We may earn a commission at no extra cost to you. Code KAREL. Disclosure
Quick summary
Phoenix combines three peptides already known in the recovery community: 1. KPV — anti-inflammatory tripeptide derived from α-MSH 2. TB-500 (Thymosin β-4 fragment) — cell migration / actin 3. BPC-157 — gastric pentadecapeptide for repair in animal models It is a product for convenience, like GLOW/KLOW: there is no paper that validates the trio together.
Studied for
How it works
Narrative sum: KPV (inflammation) + BPC/TB (tissue repair). Different mechanisms; co-formulation ≠ proven synergy.
What the research says
See the KPV, TB-500 and BPC-157 profiles. The blend has no RCTs. Compare with Wolverine (BPC+TB) and KLOW (GLOW+KPV) already on the site.
Sources
- See sources in the site's KPV, TB-500, and BPC-157 profiles
- PubMed BPC-157
- PubMed thymosin beta-4
- PubMed KPV peptide
Evidence level
D as a blend; see individual profiles (BPC/TB ~D–C preclinical; KPV ~D)
What's most reported
- Those of each component
- Injection site reaction
Common side effects
Those of its parts; added risk of a combined product (relative dose of each is unclear if the vial does not detail ratios).
Combines / does not combine
It's already a combo: do not duplicate BPC, TB, or KPV. Do not stack with GLOW/KLOW/Wolverine at the same time.
Frequently asked questions
Not as a whole.
Wolverine ≈ BPC+TB. KLOW ≈ GHK-Cu+BPC+TB+KPV. Phoenix ≈ KPV+TB+BPC (without GHK-Cu).
Keep exploring
Keep learning
Related peptides
Educational content. Not medical advice or usage guidelines. Research products are not approved medications unless otherwise indicated.